Latest News

STAT Plus: Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated in patients with advanced, triple-negative breast cancer, the biotech said Monday.

The decision to halt the study involving the Immunomedics drug called sacituzumab govitecan comes months before final results were expected and was based on a unanimous recommendation of independent study monitors following a review of the data. The monitors also weighed the possibility that the coronavirus pandemic might interfere with the study.

Continue to STAT Plus to read the full story…

Source link

Related posts

Elucidation of thermally induced internal porosity in zinc oxide nanorods


New understanding could help improve prediction and prevention of depression


Machine learning for cluster analysis of localization microscopy data


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World